<DOC>
	<DOC>NCT00297570</DOC>
	<brief_summary>The study is controlled and randomized in Philadelphia-positive chronic myeloid leukemia (Ph+ CML) patients with complete cytogenetic response after more than one year of imatinib therapy. The aim is to explore a possible benefit in the addition of peg-interferon (Peg-IFN) to imatinib, in terms of the rate of achievement, molecular remission, and response duration.</brief_summary>
	<brief_title>Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia, Myeloid</mesh_term>
	<mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Ph+ CML patients in complete cytogenetic response (CCR) after more than 1 year of imatinib therapy. Patients in imatinib study Patients with a history of intolerability to interferon. Patients with less than CCR or less than one year of imatinib therapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>CML</keyword>
	<keyword>Imatinib</keyword>
	<keyword>Pegylated Interferon</keyword>
	<keyword>Philadelphia Positive CML</keyword>
</DOC>